메뉴 건너뛰기




Volumn 29, Issue 11, 2006, Pages 1061-1067

Risk factors for rhabdomyolysis with simvastatin and atorvastatin

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ATORVASTATIN; CLARITHROMYCIN; CLOPIDOGREL; CLOZAPINE; COLCHICINE; CYCLOSPORIN A; CYPROTERONE; DANAZOL; DILTIAZEM; ERYTHROMYCIN; ESOMEPRAZOLE; FUSIDIC ACID; GEMFIBROZIL; ITRACONAZOLE; MIBEFRADIL; NEFAZODONE; QUININE; ROXITHROMYCIN; SIMVASTATIN; VERAPAMIL; WARFARIN;

EID: 33845433907     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200629110-00005     Document Type: Article
Times cited : (41)

References (28)
  • 1
    • 78651488228 scopus 로고    scopus 로고
    • Pharmaceutical Pricing Section, Pharmaceutical Benefits Branch, Government of Australia. Available from [ccessed 2006Jan 30]
    • Pharmaceutical Pricing Section, Pharmaceutical Benefits Branch, Ministry of Health and Ageing, Government of Australia. Expenditure and prescriptions twelve months to 30 June 2005 [online]. Available from URL: http://www.health. gov.au/internet/wcms/publishing.nsf/ Content/pbs-stats-pbexp-jun05-index [ccessed 2006Jan 30]
    • Expenditure and Prescriptions Twelve Months to 30 June 2005 [Online]
  • 2
    • 0037031061 scopus 로고    scopus 로고
    • MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: A randomised placebo-controlled trial
    • Heart Protection Study Collaborative Group
    • Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22
    • (2002) Lancet , vol.360 , pp. 7-22
  • 3
    • 4344683381 scopus 로고    scopus 로고
    • Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial
    • Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-96
    • (2004) Lancet , vol.364 , pp. 685-696
    • Colhoun, H.M.1    Betteridge, D.J.2    Durrington, P.N.3
  • 4
    • 11144355354 scopus 로고    scopus 로고
    • Intensive versus moderate lipid lowering with statins after acute coronary syndromes
    • Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-504
    • (2004) N Engl J Med , vol.350 , pp. 1495-1504
    • Cannon, C.P.1    Braunwald, E.2    McCabe, C.H.3
  • 5
    • 0036163750 scopus 로고    scopus 로고
    • FDA adverse event reports on statin-associated rhabdomyolysis
    • Omar MA, Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother 2002; 36: 288-95
    • (2002) Ann Pharmacother , vol.36 , pp. 288-295
    • Omar, M.A.1    Wilson, J.P.2
  • 7
    • 0037429617 scopus 로고    scopus 로고
    • Risk for myopathy with statin therapy in high-risk patients
    • Ballantyne CM, Corsini A, Davidson MH, et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 2003; 163: 553-64
    • (2003) Arch Intern Med , vol.163 , pp. 553-564
    • Ballantyne, C.M.1    Corsini, A.2    Davidson, M.H.3
  • 8
    • 0036053033 scopus 로고    scopus 로고
    • Myopathy associated with HMG-CoA reductase inhibitors (statins): A series of 10 patients and review of the literature
    • McKelvie PA, Dennett X. Myopathy associated with HMG-CoA reductase inhibitors (statins): a series of 10 patients and review of the literature. J Clin Neuromuscular Dis 2002; 3: 143-8
    • (2002) J Clin Neuromuscular Dis , vol.3 , pp. 143-148
    • McKelvie, P.A.1    Dennett, X.2
  • 9
    • 0036047090 scopus 로고    scopus 로고
    • HMG CoA reductase-inhibitor-related myopathy and the influence of drug interactions
    • Huynh T, Cordato D, Yang F, et al. HMG CoA reductase-inhibitor-related myopathy and the influence of drug interactions. Intern Med J 2002; 32: 486-90
    • (2002) Intern Med J , vol.32 , pp. 486-490
    • Huynh, T.1    Cordato, D.2    Yang, F.3
  • 13
    • 0032547751 scopus 로고    scopus 로고
    • The short life and rapid death of a novel antihypertensive and antianginal agent
    • Krum H, McNeil JJ. The short life and rapid death of a novel antihypertensive and antianginal agent. Med J Aust 1998; 169: 408-9
    • (1998) Med J Aust , vol.169 , pp. 408-409
    • Krum, H.1    McNeil, J.J.2
  • 14
    • 0031060641 scopus 로고    scopus 로고
    • Colchicine biotransformation by human liver microsomes: Identification of CYP3A4 as the major isoform responsible for colchicine demethylation
    • Tateishi T, Soucek P, Caraco Y, et al. Colchicine biotransformation by human liver microsomes: identification of CYP3A4 as the major isoform responsible for colchicine demethylation. Biochem Pharmacol 1997; 53: 111-6
    • (1997) Biochem Pharmacol , vol.53 , pp. 111-116
    • Tateishi, T.1    Soucek, P.2    Caraco, Y.3
  • 15
    • 0141706460 scopus 로고    scopus 로고
    • Metabolism and elimination of quinine in healthy volunteers
    • Mirghani RA, Hellgren U, Bertilsson L, et al. Metabolism and elimination of quinine in healthy volunteers. Eur J Clin Pharmacol 2003; 59: 423-7
    • (2003) Eur J Clin Pharmacol , vol.59 , pp. 423-427
    • Mirghani, R.A.1    Hellgren, U.2    Bertilsson, L.3
  • 16
    • 27944470435 scopus 로고    scopus 로고
    • Rhabdomyolysis: An evaluation of 475 hospitalized patients
    • Melli G, Chaudhry V, Cornblath DR. Rhabdomyolysis: an evaluation of 475 hospitalized patients. Medicine 2005; 84: 377-85
    • (2005) Medicine , vol.84 , pp. 377-385
    • Melli, G.1    Chaudhry, V.2    Cornblath, D.R.3
  • 17
    • 0036091102 scopus 로고    scopus 로고
    • Colchicine-induced rhabdomyolysis
    • Boomershine KH. Colchicine-induced rhabdomyolysis. Ann Pharmacother 2002; 36 (5): 824-6
    • (2002) Ann Pharmacother , vol.36 , Issue.5 , pp. 824-826
    • Boomershine, K.H.1
  • 18
    • 0038147266 scopus 로고    scopus 로고
    • Rhabdomyolysis causing AV blockade due to possible atorvastatin, esomeprazole, and clarithromycin interaction
    • Sipe BE, Jones RJ, Bokhart GH. Rhabdomyolysis causing AV blockade due to possible atorvastatin, esomeprazole, and clarithromycin interaction. Ann Pharmacother 2003; 37: 808-11
    • (2003) Ann Pharmacother , vol.37 , pp. 808-811
    • Sipe, B.E.1    Jones, R.J.2    Bokhart, G.H.3
  • 19
    • 33845484201 scopus 로고    scopus 로고
    • Clopidogrel (Plavix): Suspected drug interaction with atorvastatin (Lipitor) and cyclosporine resulting in rhabdomyolysis
    • [online] Available from [Accessed 2006 Sep 19]
    • Canadian Adverse Reaction Newsletter. Clopidogrel (Plavix): suspected drug interaction with atorvastatin (Lipitor) and cyclosporine resulting in rhabdomyolysis [online]. Available from URL: http://www.hc-sc.gc.ca/dhp-mps/ medeff/bulletin/carn-bcei_v15n2_e.html [Accessed 2006 Sep 19]
    • Canadian Adverse Reaction Newsletter
  • 20
    • 0033406334 scopus 로고    scopus 로고
    • Rhabdomyolysis and acute renal failure due to combination therapy with simvastatin and warfarin
    • Mogyorósi A, Bradley B, Showalter A, et al. Rhabdomyolysis and acute renal failure due to combination therapy with simvastatin and warfarin. J Intern Med 1999; 246: 599-602
    • (1999) J Intern Med , vol.246 , pp. 599-602
    • Mogyorósi, A.1    Bradley, B.2    Showalter, A.3
  • 21
    • 0031657436 scopus 로고    scopus 로고
    • Rhabdomyolysis after correction of hyponatremia due to psychogenic polydipsia possibly complicated by clozapine
    • Wicki J, Rutschmann OT, Burri H, et al. Rhabdomyolysis after correction of hyponatremia due to psychogenic polydipsia possibly complicated by clozapine. Ann Pharmacother 1998; 32: 892-5
    • (1998) Ann Pharmacother , vol.32 , pp. 892-895
    • Wicki, J.1    Rutschmann, O.T.2    Burri, H.3
  • 22
    • 14944369588 scopus 로고    scopus 로고
    • Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy
    • Rätz Bravo AE, Tchambaz L, Krähenbühl-Melcher A, et al. Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy. Drug Saf 2005; 28: 263-75
    • (2005) Drug Saf , vol.28 , pp. 263-275
    • Rätz Bravo, A.E.1    Tchambaz, L.2    Krähenbühl-Melcher, A.3
  • 23
    • 33845488099 scopus 로고    scopus 로고
    • Pharmaceutical Benefits Scheme [Online]. Available from [Accessed 2006 Jan 31]
    • Pharmaceutical Benefits Scheme, Medicare Australia [online]. Available from URL: http://www.medicareaustralia.gov.au/statistics/dyn_pbs/forms/pbs_tab1. shtml [Accessed 2006 Jan 31]
  • 24
    • 0034887738 scopus 로고    scopus 로고
    • Lipid-lowering drugs and risk of myopathy: A population-based follow-up study
    • Gaist D, García Rodríguez LA, Huerta C, et al. Lipid-lowering drugs and risk of myopathy: a population-based follow-up study. Epidemiology 2001; 12: 565-9
    • (2001) Epidemiology , vol.12 , pp. 565-569
    • Gaist, D.1    García Rodríguez, L.A.2    Huerta, C.3
  • 25
    • 9644252909 scopus 로고    scopus 로고
    • Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs
    • Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004; 292: 2585-90
    • (2004) JAMA , vol.292 , pp. 2585-2590
    • Graham, D.J.1    Staffa, J.A.2    Shatin, D.3
  • 26
    • 33645875021 scopus 로고    scopus 로고
    • Statin safety: An assessment using an administrative claims database
    • Cziraky MJ, Willey MJ, McKenney JM, et al. Statin safety: an assessment using an administrative claims database. Am J Cardiol 2006; Suppl. 97: 61C-8C
    • (2006) Am J Cardiol , vol.97 , Issue.SUPPL.
    • Cziraky, M.J.1    Willey, M.J.2    McKenney, J.M.3
  • 27
    • 4544243333 scopus 로고    scopus 로고
    • Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes
    • de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes. JAMA 2004; 292: 1307-16
    • (2004) JAMA , vol.292 , pp. 1307-1316
    • De Lemos, J.A.1    Blazing, M.A.2    Wiviott, S.D.3
  • 28
    • 24144437144 scopus 로고    scopus 로고
    • Conversion to atorvastatin in patients intolerant or refractory to simvastatin therapy: The CAPISH Study
    • Krasuski RA, Doeppenschmidt D, Henry JS, et al. Conversion to atorvastatin in patients intolerant or refractory to simvastatin therapy: The CAPISH Study. Mayo Clin Proc 2005; 80: 1163-8
    • (2005) Mayo Clin Proc , vol.80 , pp. 1163-1168
    • Krasuski, R.A.1    Doeppenschmidt, D.2    Henry, J.S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.